仙琚製藥(002332.SZ):潑尼松龍片獲得美國FDA批准
格隆匯5月6日丨仙琚製藥(002332.SZ)公佈,近日,浙江仙琚製藥股份有限公司收到美國食品藥品監督管理局(簡稱“美國FDA”)的通知,公司向美國FDA申報的潑尼松龍片的簡略新藥申請(ANDA,即美國仿製藥申請)已獲得批准。
潑尼松龍片為糖皮質激素類藥物,超生理量的糖皮質激素具有抗炎、抗過敏和抑制免疫等多種藥理作用。主要用於過敏性與自身免疫性炎症性疾病,膠原性疾病。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.